AbbVie (ABBV) Earns Coverage Optimism Rating of 0.23
Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AbbVie earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.5509898537333 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s scoring:
- AbbVie’s HCV Combo Drug Mavyret Clinches Approval in Canada (mrtopstep.com)
- AbbVie : s MAVIRET Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes (4-traders.com)
- Lam Research Corporation (LRCX) Shares Sold by Pioneer Investment Management Inc (currenthollywood.com)
- AbbVie’s HCV Combo Drug Mavyret Clinches Approval in Canada (zacks.com)
- AbbVie’s HCV Combo Drug Mavyret Clinches Approval in Canada – Nasdaq (nasdaq.com)
AbbVie (NYSE:ABBV) traded up 0.16% during mid-day trading on Friday, reaching $69.96. 4,016,367 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $71.72 and a 200-day moving average of $67.10. The stock has a market cap of $111.52 billion, a price-to-earnings ratio of 17.21 and a beta of 1.50. AbbVie has a one year low of $55.06 and a one year high of $75.04.
AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. The company had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 earnings per share. On average, equities research analysts anticipate that AbbVie will post $5.52 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 15th. Investors of record on Friday, July 14th were issued a dividend of $0.64 per share. The ex-dividend date of this dividend was Wednesday, July 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 3.66%. AbbVie’s dividend payout ratio is presently 62.90%.
ABBV has been the subject of a number of research reports. Vetr raised shares of AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 target price for the company in a report on Monday, May 8th. Credit Suisse Group reissued a “neutral” rating and issued a $74.00 target price (up previously from $65.00) on shares of AbbVie in a report on Thursday, July 20th. BMO Capital Markets set a $63.00 target price on shares of AbbVie and gave the stock a “hold” rating in a report on Thursday, April 27th. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Finally, Leerink Swann reissued a “market perform” rating on shares of AbbVie in a report on Thursday, June 22nd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $76.02.
TRADEMARK VIOLATION NOTICE: “AbbVie (ABBV) Earns Coverage Optimism Rating of 0.23” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/19/abbvie-abbv-earns-coverage-optimism-rating-of-0-23.html.
In related news, Chairman Richard A. Gonzalez sold 193,131 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the completion of the transaction, the chairman now owns 469,623 shares in the company, valued at $33,343,233. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Laura J. Schumacher sold 79,800 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $70.00, for a total value of $5,586,000.00. Following the transaction, the insider now owns 187,625 shares of the company’s stock, valued at approximately $13,133,750. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 490,491 shares of company stock valued at $34,684,639. 0.23% of the stock is owned by corporate insiders.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.